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Abstract 
 Vascular Endothelial Growth Factor (VEGF) is important for blood vessel 
development in a variety of tissues including an ovarian structure, the corpus luteum 
(CL).  The CL is a transient endocrine gland that secretes progesterone, which prepares 
the uterus for pregnancy. In the absence of pregnancy, the corpus luteum regresses in 
response to endogenous prostaglandin (PG) F2α. Deficiencies in luteal function during 
early pregnancy may result in embryonic loss. Understanding of the mechanisms of luteal 
function could aid in the development of new methods to regulate fertility.  
 Corpora lutea are susceptible to the luteolytic effects of PGF2α  after day 4 of the 
luteal phase; prior to that time the CL does not regress in response to treatment with 
PGF2α. The mechanisms responsible for the acquisition of responsiveness to PGF2α and 
the specific intracellular mediators of PGF2α induced luteolysis are unclear. 
 The objectives of this research were to investigate if exogenous PGF2α affects 
VEGF mRNA expression in sheep corpora lutea and to determine if the effect is 
dependent upon whether the corpus luteum has not (early luteal phase CL) or has (mid-
luteal phase CL) acquired luteolytic capacity.  
  Mature female sheep (n=18) were randomly separated into two groups (early 
luteal phase, day 3, and mid-luteal phase, day 10). Each group was divided into two 
treatment groups, PGF2α  treated and saline-treated (control). From each animal, one CL 
was removed at 2h and a second CL was removed 24h after treatment. Total RNA was 
isolated from each CL, purified, and verified for integrity. Real-time Polymerase Chain 
Reaction (PCR) was used for relative quantification of VEGF mRNA. The real-time 
methods were optimized and validated using two endogenous reference genes; β-actin 
and L-19. The quantity of VEGF mRNA present in each sample was standardized using 
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the reference genes and was expressed as fold change from the mean value for the control 
CL collected on day 3 at 2h.  Luteal progesterone concentrations were determined using 
radioimmunoassay. Data were analyzed using analysis of variance for a split plot design 
with sheep as the main plot and CL as the sub-plot.    
 Quantities of VEGF mRNA were similar among CL collected during the early 
versus mid-luteal phase in the control animals (p>0.05). PGF2α had no effect on VEGF 
mRNA levels in early luteal phase CL collected at 2h or 24h after injection (p>0.05). In 
contrast, on day 10 of the estrous cycle, PGF2α treatment resulted in a marked reduction 
of VEGF expression within 24h after injection (p=0.002); it is unclear if VEGF 
expression was changed during the first 2h after PGF2α administration at this stage of the 
cycle.     
 There was no effect of PGF2α on luteal concentrations of progesterone during the 
early luteal phase (p>0.05).  This is consistent with the expected lack of response at this 
stage. In contrast, PGF2α caused a decrease (p=0.03) in luteal progesterone in mid-luteal 
phase CL, demonstrating that these corpora lutea have acquired luteolytic capacity.  
 Since the mid-cycle CL has acquired luteolytic capacity, it will regress in 
response to PGF2α.  As such, the decline in the message for VEGF was associated with 
luteal regression.  We conclude that inhibition of VEGF and subsequent vascular 
destabilization may be an important component of the luteolytic cascade invoked by 
PGF2α.  
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Introduction 
 Vascular Endothelial Growth Factor (VEGF) is essential for blood vessel 
development during fetal development, wound healing, fat deposition, and malignant 
tumor propagation (23). VEGF also plays an important role in ovarian function. For 
example, VEGF participates in the development of follicles, which are structures on the 
ovary that house the female gametes (25). It is also essential in the extensive 
vascularization of the corpus luteum (CL), a specialized ovarian gland necessary for 
maintenance of pregnancy (20, 21, 23). 
VEGF is an angiogenic glycoprotein that binds to specific receptors on 
endothelial cells. VEGF consists of eight exons separated by seven introns. Five VEGF 
isoforms resulting from alternative splicing of the single VEGF gene have been identified 
in mammals. VEGF189, VEGF165, and VEGF121 have been detected in the majority of 
cells and tissues which express the VEGF gene in humans. Various mammalian species 
may differ in the exact number of amino acids present in VEGF.  For example, sheep 
VEGF has one less amino acid than the human VEGF, therefore the predominant VEGF 
isoforms in sheep are VEGF188, VEGF164, and VEGF120 (7). 
VEGF is a primary angiopoietin, helping to form primary capillary networks in 
previously avascular tissue during angiogenesis. Angiogenesis consists of 3 main steps: 
the breakdown of existing blood vessels; the migration of endothelial cells towards a 
stimulus; and the proliferation of endothelial cells to establish a new blood vessel sprout 
(9, 25, 31).  
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Controlled, cyclical, angiogenesis occurs naturally in the adult female in the ovary 
and corpus luteum. Within each estrous cycle, the CL develops from an ovulatory follicle 
through a process known as luteinization, which begins directly after ovulation (24). 
Luteinization is dependent upon angiogenesis and in order for the CL to be functional and 
fulfill its endocrine function, a rich vascular network must be developed (9, 25). The CL 
increases in size from the time of ovulation until midway through the luteal phase. This 
increase is due to a three fold increase in the size of the large luteal cells and a five fold 
increase in the number of small luteal cells (16). Seventy-five percent of the cells in a 
mature CL are vascular. The mature corpus luteum has one of the highest blood supplies 
of any organ on a per gram of tissue basis and the growth of this blood supply typically 
occurs within the first six days of development.  
Regression of the CL is termed luteolysis and is dependent upon prostaglandin 
F2α (PGF2α), which is produced by the endometrial lining of the uterus. It has been shown 
that PGF2α is a primary luteolysin for many species (1, 3, 4, 25, 30).  Exogenous PGF2α 
causes luteolysis in sheep when administered during the mid-luteal phase but not when 
administered in the first four days after ovulation (17, 24). A similar effect has been seen 
in cattle (28). Exogenous PGF2α is widely used to synchronize estrus. It can also be used 
to induce abortions or parturition (24, 28). 
Although there have been numerous studies done on the hormonal regulation of 
the CL, there is still much to learn about the mechanisms behind its development and 
regression within the ovary. Studies have been done to determine the effects of PGF2α on 
a number of regulatory hormones and receptors within the ovary including progesterone, 
progesterone receptors, estradiol, glucocorticoids, and androgens (1, 5, 7, 27). Studies 
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have also looked at the changes of VEGF mRNA levels in developing female rats (8, 13), 
humans (5), and rhesus monkeys (10) throughout different stages of the estrous cycle. 
Although VEGF is an essential factor in luteal vascularization (5, 13, 22, 25) and PGF2α 
induces many changes in the CL leading to luteolysis (1, 5, 7), there has been limited 
research done studying the effects of PGF2α on VEGF expression during luteal formation 
and regression. VEGF could prove to be an important component of luteal maintenance.  
The objective of the present study was to determine if PGF2α affects the 
concentrations of VEGF mRNA in sheep corpora lutea. This experiment was designed to 
examine the acute (within 2h) vs. chronic (within 24h) effects of  PGF2α on VEGF 
expression in CL that have not (early luteal phase CL) or have (mid-luteal phase CL) 
acquired luteolytic capacity. 
Materials & Methods 
Experimental model and collection of CL: 
 Mature female sheep (n=18) obtained from the Ohio State University Sheep 
facility were used in this study. The sheep were randomly separated into two groups 
(early luteal phase, day 3, and mid-luteal phase, day 10). Each group was divided into 
two treatment groups, PGF2α-treated and saline-treated (control). Two CL were removed 
from each animal.  The first one was removed at 2h and the second at 24h post treatment 
(Fig. 1).  
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Figure 1. Experimental Design  
 
 The onset of estrus (day 0) was determined by twice daily observation in the 
presence of a vasectomized ram. On the assigned day of treatment (day 3 or day 10), 
animals were transported to the surgical facility. Ewes were sedated using pentothal. The 
plane of anesthesia was maintained throughout the procedure using halothane gas. A mid 
ventral laparotomy was performed to expose the reproductive tract. Ewes received 
intramuscular injections of PGF2α (25mg dose, Lutalyse; Pharmacia & Upjohn, 
Kalamazoo, MI) or saline (time 0). The first CL was removed 2h post-treatment. A 
second CL was removed 24h post-treatment. 
 Luteal tissues were immediately snap frozen in liquid nitrogen. Samples were 
stored at -80°C. A portion of each CL was used to determine tissue progesterone 
concentrations by radioimmunoassay.  
Adult Ewes 
(n=18) 
Group 1 
Early Cycle (n=9) 
Group 2 
Mid Cycle (n=9) 
Administration of PGF2α 
(n=5) 
Saline Control 
(n=4) 
Administration of PGF2α 
(n=5) 
Saline Control 
(n=4) 
2h 
(n=5) 
24h 
(n=5) 
2h 
(n=4) 
24h 
(n=4)
2h 
(n=5) 
24h 
(n=5) 
2h 
(n=4)
24h 
(n=4)
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RNA isolation and purification:  
 RNA was isolated and purified from each CL using RNeasy® Mini Kit (Qiagen 
Inc., Valencia, CA). RNA purity and integrity was determined using the RNA NanoDrop 
by measuring the absorbance of each sample at 260 nm (A260) and 280 nm (A280). An 
absorbance of 1 unit at A260 corresponds to a 40 μg/ml RNA concentration. The total 
concentration of RNA in each sample was then determined according to the equation:  
 40 x A260 x dilution factor = concentration of RNA in sample (μg/ml). 
The purity of the RNA sample with respect to contaminants that absorb UV light was 
estimated by determining the ratio of the absorbance readings at 260 nm and 280 nm 
(A260/A280) (2). Samples were also analyzed using the Bioanalyzer (Microarray Core 
Facility, OSU Comprehensive Cancer Center, Columbus, OH) to determine the RNA 
integrity. Isolated RNA was stored at -80°C. 
Real Time PCR validation: 
 Two endogenous reference genes were selected to validate the real time PCR 
methods. β-actin is a structural protein present in most eukaryotic cells. β-actin has been 
used as an endogenous control in other reproductive studies (6, 26). L-19 is a ribosomal 
protein that remains fairly constant throughout the luteal phase (1).  
 Primers for L-19, β-actin, and VEGF120 were used for reverse transcription of 
RNA from the exogenous control using SuperScript One-Step Kit (InVitrogen, Carlsbad, 
CA). Products were run on a 10% tris-boric acid with EDTA (TBE) gel (Bio-Rad 
Laboratories, Hercules, CA) and bands were visualized using UV light following staining 
with ethidium bromide to ensure that each set of primers amplified a product of the 
expected size and that only one product was being generated. 
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 SYBR Green real-time RT-PCR was used to quantify levels of L-19, β-actin, and 
VEGF120 present in each sample.  SYBR Green is a method of PCR that utilizes a 
fluorescent molecule to quantify the amount of product present. The SYBR Green dye 
will only fluoresce when it is intercalated into a double stranded DNA product, however, 
it is not sequence specific. More double-stranded product is created with each cycle of 
amplification and the level of fluorescence increases proportionally. Sample 
concentration is measured by determining how many amplification cycles are needed to 
reach a threshold level of fluorescence.  
 It was necessary to determine an appropriate amount of RNA to include in each 
sample so that threshold fluorescence levels were not reached too early or late in the run; 
fifteen to twenty-five cycles were desirable. Each set of primers was combined with 10 
fold increasing increments of exogenous control RNA and analyzed using SYBR Green 
real-time RT-PCR. The following amounts of sample RNA were used: 0.002ng, 0.02ng, 
0.2ng, 2.0ng, 20.0ng and 200.0ng. It was determined that 20ng of sample RNA was to be 
used for each run. These samples were also used to generate efficiency curves to 
determine the efficiency of each primer. The efficiencies are used in the Pfaffl 
calculations (Equation 1).  
 Because SYBR Green is not a sequence specific method, it was necessary to 
determine that there were not multiple products contributing to the fluorescence level. 
Besides verifying this using gel electrophoresis (above), we also generated melting 
curves for each sample after the reverse-transcription and amplification were complete. If 
the product is homogeneous, a single peak will be seen.  
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 Endogenous reference genes are critical when using the Pfaffl method to quantify 
RNA concentrations in real-time RT-PCR (15). The endogenous reference gene is used to 
correct samples for technical variation during the sample preparation. The concentrations 
of an effective reference gene should not vary between different samples due to time or 
treatment. Because endogenous reference genes are so important to the interpretation of 
the results for this study, both L-19 and β-actin were utilized to help ensure that we 
would have at least one reference gene that fit the above criteria. 
 A day 10, 2h, untreated animal was designated as the exogenous control. This 
animal was not included in the results and analysis. The RNA isolated from the animal 
was used to validate the RT-PCR methods. This sample was also run in each PCR sample 
run. This exogenous control ensured that runs were working properly and data remained 
consistent among different runs.  
 Day 3, 2h, untreated animals were chosen to be the study control (control in 
equation 1). The mean level of RNA present in these four corpora lutea was set as a 
baseline to measure either increases or decreases in VEGF120 dependent upon time and/or 
treatment. 
Primer Design: 
 β-actin forward and reverse primers were obtained from Dr. Danforth (6, 26). L-
19 forward and reverse primers were obtained from Dr. Cárdenas (1). The VEGF120 
primers were designed using InVitrogen’s online custom primer resources. The VEGF120 
sequence was determined by referencing work which outlined the specific exons present 
in each VEGF isoform (Fig. 2) (7, 13, 16). These exons were then compared to the 
human VEGF isoform sequences which are similar to ovine VEGF using the GenBank 
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available through National Institutes of Health. Sequences specific to the VEGF120 
isoform were selected so that a 152 base pair product would be generated. The reverse 
primer used in this study spans a segment between exons 5 and 8 (Fig. 2). VEGF120 is the 
only isoform that does not have any exons between exon 5 and 8, therefore this reverse 
primer will only bind to the VEGF120 isoform. Designed primers were obtained from 
InvitrogenTM (InVitrogen Corporation, Carlsbad, CA). The following sequences were 
used for VEGF120 primers:  
Forward (5’ to 3’) -  TTATGCGGATCAAACCTCAC 
Reverse (5’ to 3’) – TCACATTTTTCTTGTTGC 
 
 
Figure 2. Human VEGF splice variants (VEGF121, VEGF165, and VEGF189). 
Figure taken from Wellman, Taube et al. (29). Figure refers to human isoforms of VEGF 
which differ from ovine VEGF by 1 amino acid, hence the one codon difference in all 
nomenclature. 
 
 
VEGF Survey:  
 In addition to designing primers specific to VEGF120, primers were also designed 
that would survey a number of VEGF isoforms including VEGF120, VEGF145, VEGF164, 
VEGF182, VEGF184, and VEGF205. This was done by referencing the previous work using 
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VEGF sequences and isoforms (Fig. 2) as well as GenBank (National Institutes of 
Health) (7, 13, 16). The designed primers were obtained from InvitrogenTM (Invitrogen 
Corporation, Carlsbad, CA). 
 Primers were combined with RNA from the exogenous control as well as from 
samples from each of the treatment groups. Samples were reverse-transcribed and run on 
a TBE gel (Bio-Rad Laboratories, Hercules, CA). Bands were visualized using UV light 
after staining with ethidium bromide. This allowed a quick visualization of the various 
VEGF isoforms present in the control and treated CL. The following sequences were 
used for VEGFsurvey primers:  
Forward (5’ to 3’) -  TTATGCGGATCAAACCTCAC 
Reverse (5’ to 3’) – GGAGGCTCCTTCCTCCAG 
Real-time RT PCR Analysis: 
 Once the system had been validated using the exogenous control, samples were 
run using the optimized methods (19). All samples were run in triplicate in a 96-well 
plate. All three sets of primers were run with each sample within the same plate. Samples 
from each of the four main treatment groups were selected at random and run on each 
plate. The exogenous control was also run in triplicate with each set of primers on each 
plate. QuantiTect® SYBR® Green RT-PCR Kit (Qiagen Inc., Valencia, CA) was used to 
prepare all samples according to manufacturer’s instructions. 20ng of RNA was used in 
each sample well. Total reaction volume was 25μl. No transcript (NT) samples 
containing SYBR Green reagent and primers, but no sample RNA were also run in 
triplicate for each primer on each plate to ensure no contamination within the reaction 
reagents. 
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 Samples were run using ABI 7900 Real-Time PCR system (ABI, Columbia, MD). 
Samples underwent 40 amplification cycles and the fluorescence levels were measured. 
Disassociation curves were generated for each sample. 
Data Analysis: 
 The real-time PCR efficiencies (E) of target and reference genes were determined 
from the concentration curves created using the exogenous control.  CT value versus the 
log of starting amount of RNA (ng) was plotted and the slope of the line was determined 
for each gene. E was then calculated according to the equation E=10[-1/slope] (15, 18, 19).  
The quantity of mRNA present in each sample was standardized using the reference 
genes according to the Pfaffl equation (Equation 1). 
 
Fold Change = (Etarget)∆CT*/ (Ereference)∆CT** 
Equation 1. Pfaffl Equation (15). 
*(CT VEGFcontrol – CT VEGFsample) 
** (CT Reference Genecontrol – CT Reference Genesample) 
 
 The quantity of VEGF mRNA present in each sample was expressed as fold 
change from the mean value for the control CL collected on day 3 at 2h (designated 
control). Analysis was completed using both L-19 and β-actin as reference genes. 
 Data were analyzed using analysis of variance for a split plot design with sheep as 
the main plot and CL as the sub-plot. 
Luteal Progesterone Concentrations: 
 Luteal progesterone concentrations were determined using radioimmunoassay 
(RIA). These assays were completed by Ottobre and Gaddis prior to the beginning of this 
study. They used a proven and specific antibody (GDN 337; donated by G. Niswender, 
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Colorado State University) previously validated in sheep blood (11).  Luteal tissue was 
homogenized in Tris-buffered saline.  Luteal homogenates were extracted using 
petroleum ether prior to RIA.  The progesterone assay has been validated in our 
laboratory for primate serum and luteal incubate (12) and porcine plasma and luteal 
homogenate (14).  A standard curve with a slope of approximately –1.0 after log/logit 
transformation was first established using 2.5-500 pg progesterone standards. This assay 
was validated for ovine luteal homogenate by showing that when increasing volumes of 
homogenate (10 μl - 200 μl) were extracted and assayed for progesterone content, values 
were parallel to the standard curve.  All samples from each animal were run in duplicate 
within the same assay.  The inter-assay and intra-assay coefficient of variation for the 
progesterone assay were 12.3% and 8.4% + 1.4%, respectively.   
Results 
 The VEGF survey primers identified several VEGF isoforms in all samples tested. 
Distinct bands were visualized at 152 base pairs and 283 base pairs, which are consistent 
with the VEGF120 and VEGF164 isoforms. Another prominent band was seen at the top of 
the gel which may be either VEGF189 or VEGF205, however, the exact length of exon 6 is 
unknown and the exact molecular weight of these isoforms within the sheep are still 
unknown. In addition to these distinct bands, many light bands were seen that represent 
the numerous other isoforms and fragments of VEGF. No difference in concentrations 
between the control and treated samples could be determined by band visualization (Fig. 
3). 
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                                     1     2     3    4      5    6     7     8    9   10    11   12 
 
Figure 3.  Visualization of VEGF Survey Primers 
Samples in lanes 1-12 are listed below. All samples were amplified with the VEGF 
survey primers and run on a TBE Gel. Gel was visualized using UV light after staining 
with ethidium bromide.  
 
Lane / Sample   Lane / Sample         Lane / Sample 
1 Ladder (25 BP marker) 5 Day 3, 24h, PGF2α 9 Day 10, 24h, PGF2α 
2 Day 3, 2h, Control 6 Day 10, 2h, control 10 Exogenous Control 
3 Day 3, 24h, Control 7 Day 10, 24h, control 11 Exogenous Control 
4 Day 3, 2h, PGF2α 8 Day 10, 2h, PGF2α 12 No Transcript 
 
 Disassociation curves displayed a single large peak for each sample (Fig. 4), 
which represents a homogenous product. Small disassociation peaks not consistent with 
sample disassociation peaks were seen in the NT samples. NT samples also increased in 
fluorescence at higher cycle values. This is consistent with primer dimers that can form in 
the absence of transcript (Fig. 5).  
 Quantities of RNA for both β-actin and L-19 remained constant throughout all of 
the samples regardless of the sample time or treatment, and individual analyses were 
done using each gene. 
283 (VEGF164) 
152 (VEGF120) 
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 CT values for VEGF mRNA were noticeably higher 24 hours after animals were 
treated on day 10 (Fig. 5). 
 
 
 
 
 
 
 
 
 
Figure 4. Dissociation curve for SYBR Green PCR run (VEGF120). 
Figure represents disassociation of VEGF120 product run with triplicate samples from 
each of the four main treatment groups. Temperature is plotted on the x-axis with the 
derivative of the fluorescence level on the y-axis. The disassociation of each sample has a 
peak at the same temperature however; the NT samples can be seen to have small 
amounts of double stranded material present. 
 
NT Samples
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Figure 5. Amplification plot for SYBR Green PCR run (VEGF120). 
Figure represents amplification of VEGF120 product run with triplicate samples from each 
of the four main treatment groups. Cycle number is plotted on the x-axis with level of 
fluorescence on the y-axis. The threshold fluorescence level is depicted by the red line. 
Samples from CL removed 24 hours after treatment for animals treated on Day 10 can be 
seen crossing the fluorescence threshold after approximately 25 cycles (B) while all other 
treatment groups cross the threshold after 20 cycles (A). The NT samples cross the 
fluorescence threshold after approximately 30 cycles (C). 
 
 Quantities of VEGF mRNA were similar among CL collected during the early 
versus mid-luteal phase in the control animals (Figs. 6 & 7, p>0.05). PGF2α had no effect 
on VEGF mRNA levels in early luteal phase CL collected at 2h or 24h after injection 
(p>0.05). In contrast, on day 10 of the estrous cycle, PGF2α treatment resulted in a 
marked (i.e., 10 fold, p=0.002) reduction of VEGF expression within 24h after injection. 
A significant increase was seen in VEGF expression 2h after PGF2α administration when 
analyzed using L-19 however, this trend was not mirrored in the β-actin corrected data so 
it remains unclear if VEGF expression was changed during the first 2h after PGF2α 
administration. 
A
B
C
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                    Early LP                                      Mid LP 
           2h                     24h                      2h                     24h      
Figure 6. Fold change in VEGF mRNA in CL standardized using β-actin 
Values for each study represent means +/- SE. An asterisk (*) represents significant 
differences between control and treated values. Data are from n=4 sheep for each control 
group and n=5 for each PGF2α-treated group. In each group, one CL was removed 2 hr 
after treatment while a second CL was removed 24 hr after treatment. Quantities of 
VEGF mRNA were similar among CL collected during the early versus mid-luteal phase 
(LP) in the control animals (p>0.05). On day 10 of the estrous cycle, PGF2α treatment 
resulted in a marked (i.e., 10 fold, p=0.002) reduction of VEGF expression within 24h 
after injection.  
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                                            Early LP                                      Mid LP 
            2h                     24h                      2h                     24h      
Figure 7. Fold change in VEGF mRNA in CL standardized using L-19 
Values for each study represent means +/- SE. An asterisk (*) represents significant 
differences between control and treated values. Data are from n=4 sheep for each control 
group and n=5 for each PGF2α-treated group. In each group, one CL was removed 2 hr 
after treatment while a second CL was removed 24 hr after treatment.  Quantities of 
VEGF mRNA were similar among CL collected during the early versus mid-luteal phase 
(LP) in the control animals (p>0.05). On day 10 of the estrous cycle, PGF2α treatment 
resulted in a small but significant increase (p=0.002) in VEGF expression 2 hours after 
injection. On day 10 of the estrous cycle, PGF2α treatment resulted in a marked (i.e., 5 
fold, p=0.002) reduction of VEGF expression within 24h after injection. 
 
 There was no effect of PGF2α on luteal concentrations of progesterone during the 
early luteal phase (Fig. 8, p>0.05).  This is consistent with the expected lack of response 
at this stage. In contrast, PGF2α caused a decrease (p=0.03) in luteal progesterone in mid-
luteal phase CL (both 2h and 24h after PGF2α administration), demonstrating that these 
corpora lutea have acquired luteolytic capacity. 
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                        Early LP                                      Mid LP 
                2h                     24h                      2h                     24h    
Figure 8. Progesterone concentrations in corpora lutea  
Values for each study represent means +/- SE. An asterisk (*) represents significant 
differences between control and treated values. Data are from n=4 sheep for each control 
group and n=5 for each PGF2α-treated group. In each group, one CL was removed 2 hr 
after treatment while a second CL was removed 24 hr after treatment.  There was no 
effect of PGF2α on luteal concentrations of progesterone during the early luteal phase 
(LP) (p>0.05).  This is consistent with the expected lack of response at this stage. In 
contrast, PGF2α caused a decrease (p=0.03) in luteal progesterone in mid-luteal phase CL 
(both 2h and 24h after PGF2α administration). 
 
Discussion 
 PGF2α causes a significant decrease in VEGF mRNA concentrations 24 hours 
after treatment in mid luteal phase CL, but not in early luteal phase CL. This coincides 
with the acquisition of luteolytic capacity, as such capacity is present by day 10 of the 
luteal phase. 
 The response of VEGF120 can be compared to that of progesterone. Neither show 
any marked decrease in the early luteal phase CL but do show a significant decrease in 
concentration in the mid luteal phase CL. These two products both are affected by the 
ability of the CL to regress. Progesterone is an endocrine product secreted by luteal cells 
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in a functional corpus luteum. Therefore, it makes sense that there is an acute, sustained 
decrease in concentration as the CL begins to undergo regression. VEGF120 plays a 
structural role within the CL and is locally acting rather than an endocrine product. 
 Another interesting comparison can be made between the VEGF data and data 
acquired from Ottobre and Gaddis on work done involving changes in Vitamin C 
concentrations throughout the luteal phase due to treatment with exogenous PGF2α. 
Ottobre and Gaddis measured the change in vitamin C concentrations in relation to the 
day of the cycle and to the treatment with PGF2α. Treatment with PGF2α causes a 
decrease in vitamin C concentrations both in the early and mid luteal phase. However, in 
the early luteal phase, vitamin C concentrations are decreased at 2 hours post treatment 
but have returned to normal levels by 24 hours post treatment. An overall increase in 
vitamin C concentrations between day 3 and day 10 is also observed. 
 These data are of great interest, because they show that the early luteal phase CL 
is responsive to PGF2α treatment, even though the CL has not acquired lutealytic capacity. 
This helps us to understand that PGF2α has pathway specific effects throughout the entire 
luteal phase. 
 The decrease in VEGF120 mRNA concentrations in mid but not early luteal phase 
CL should not be surprising. VEGF is a vascularizing protein and the early luteal phase 
CL is an intact gland that requires a high degree of vascularization to function. However, 
as a CL undergoes regression there is no need for vascular proliferation. The delayed 
effect of PGF2α on the concentrations of VEGF120 reinforces the belief that VEGF plays a 
structural role within the CL, rather than a functional role. Though the function of the CL 
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may be affected soon after treatment of PGF2α, the structural changes that occur with 
regression take longer to materialize.  
 Since the mid-cycle CL has acquired luteolytic capacity, it will regress in 
response to PGF2α.  As such, the decline in the message for VEGF was associated with 
luteal regression.  We conclude that inhibition of VEGF and subsequent vascular 
destabilization may be an important component of the luteolytic cascade invoked by 
PGF2α. It is currently still unclear whether PGF2α has a direct effect on VEGF 
concentrations or if the effects are an indirect result of the luteolytic process. Future 
studies might look directly at the effects of PGF2α on VEGF concentration present in 
luteal tissue rather than studying concentrations of mRNA.  
A better understanding of the mechanisms behind luteal development and 
regulation could aid in the development of new methods to increase fertility and 
synchronize estrus. Alternatively, by controlling luteal regression, one would have the 
means for compromising fertility. The functional corpus luteum inhibits ovulation and is 
essential for maintaining pregnancy. In the absence of pregnancy, the corpus luteum 
regresses in response to PGF2α. The loss of the corpus luteum during early pregnancy 
leads to miscarriages and spontaneous abortions (7, 24, 30).  
 This is of great interest to the livestock industry. In the beef industry, heifer cattle 
grow faster and have a much higher feed efficiency if they are not pregnant. If the corpus 
luteum could be maintained in the absence of pregnancy, ovulation and therefore 
pregnancies would be prevented. In contrast, a better understanding of how the corpus 
luteum functions to maintain pregnancy could lead to a decrease in the number of 
spontaneous abortions within herds. 
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 This research is not only beneficial to the livestock industry, but the human health 
fields as well. As women are waiting longer to have children, fertility treatments and 
alternatives are becoming increasingly important. Corpora lutea regulation has 
similarities across many mammalian species. The methods of enhancing or interrupting 
fertility may be applicable to a human model.  
 VEGF plays a role in many fields outside of reproduction. Vascularization is 
involved in wound healing and tumor proliferation. The complex mechanisms of 
development and rapid growth of the CL are very similar to mechanisms involved in 
tumor growth and wound healing (22, 23).  Tissues within the adult female reproductive 
system, much like tissues of tumors, proliferate at extremely high rates as compared to 
endothelial cells. The ovarian corpus luteum is able to double in size and cell number 
every sixty to seventy hours (22). The ovary is the only site where rapid cell proliferation 
occurs in a highly controlled, cyclical state. These attributes make the corpus luteum an 
excellent model for studying tumor proliferation. A better understanding of the regulation 
of angiogenesis (blood vessel development) and VEGF expression within the ovary can 
lead to new treatments for tumors and wounds. 
 The ability to regulate VEGF expression within the body would be a powerful 
medical tool in both animal and human medicine.  
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